Skip to main content

Table 4 Prognostic factor analysis (univariate).

From: Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis

 

OS (months)

95% CI

P value

Age

   

   < median

15.2

11.5 - 19.0

0.491

   ≧ median

12.8

7.1 - 18.4

 

Gender

   

   male

13.2

9.8 - 14.8

0.49

   Female

16.8

10.7 - 22.8

 

Performance status

   

   0-1

15.2

12.0 18.5

0.01

   ≧ 2

7.6

0 - 16.5

 

Disease status

   

   Advanced

15.2

11.7 - 18.8

0.24

   Recurrent

12.1

9.1 - 15.1

 

Histology

   

   differentiated

14.5

9.1 - 18.2

0.357

   undifferentiated

14.6

11.0 - 18.2

 

No. of organs involved

   

   1

12.8

10.1 - 15.4

0.414

   ≧ 2

16.9

14.4 - 19.3

 

Liver metastasis

   

   No

16.0

12.7 - 19.3

0.237

   Yes

10.4

3.5 - 17.3

 

Peritoneum metastasis

   

   No

15.1

9.5 - 20.7

0.54

   Yes

14.6

11.1 - 18.1

 

Tumor response

   

   No (SD or PD)

8.6

6.0 - 11.2

<0.001

   Yes (PR)

18.2

12.7 - 23.7

 

Second-line chemotherapy

   

   No

8.6

4.2 - 13.0

0.024

   Yes

16.3

15.0 - 17.5

 
  1. OS, median overall survival